Elisabeth Greiner

Partner

Dr. rer. nat. Mag. pharm.

Dr. Elisabeth Greiner is a German and European Patent Attorney and partner at df-mp. A primary focus of her practice is on opposition and litigation of German and European patents, in particular, in the fields of pharmaceuticals, chemistry and biotechnology, and provides corresponding infringement and validity opinions. She has successfully enforced and/or defended her clients’ interests in various high profile patent disputes.

+ 49 89 210 296 0
elisabeth.greiner@df-mp.com

Elisabeth Greiner

Partner

Dr. rer. nat. Mag. pharm.

Dr. Elisabeth Greiner is a German and European Patent Attorney and partner at df-mp. A primary focus of her practice is on opposition and litigation of German and European patents, in particular, in the fields of pharmaceuticals, chemistry and biotechnology, and provides corresponding infringement and validity opinions. She has successfully enforced and/or defended her clients’ interests in various high profile patent disputes.

+ 49 89 210 296 0
elisabeth.greiner@df-mp.com

practice areas.

Dr. Greiner's practice focuses on prosecution, opposition and litigation matters concerning German and European patents. With her experience in contentious proceedings, Elisabeth assists her clients with drafting, prosecuting, and assessing patent applications in various fields of life-sciences and chemistry, and has furthermore comprehensive expertise in advising on supplementary protection certificates and coordinating the filing and prosecution of corresponding applications in Germany and throughout Europe.

Elisabeth holds a PhD in pharmaceutical sciences from the University of Innsbruck, Austria, where she also received her doctorate degree for her work in the field of synthetic medicinal chemistry on CNS drugs. Elisabeth honed her in skills as medicinal chemist during her postdoctoral study at the national Institute of Health in Bethesda, MD, USA.

 

df-mp recommended as a top-tier law firm
df-mp recommended as a top-tier law firm

We are plea­sed to be recom­men­ded again in the latest…

df-mp recommended in JUVE Patent Germany Ranking 2021
df-mp recommended in JUVE Patent Germany Ranking 2021

We are deligh­ted to be lis­ted again in this year’s…

IAM Patent 1000: The world's leading patent attorneys 2021
IAM Patent 1000: The world's leading patent attorneys 2021

df-mp joins the ranks of “high­ly recom­men­ded” patent law firms…

df-mp among the most recommended patent firms
df-mp among the most recommended patent firms

We proud­ly announ­ce that df-mp is among the most recom­men­ded patent…

df-mp and Ceva win against Bayer
df-mp and Ceva win against Bayer

Sucess for Ceva: The com­pa­ny is now allo­wed to mar­ket its…

Five IP stars for df-mp
Five IP stars for df-mp

df-mp is proud to recei­ve ano­ther five IP stars this…

Success for Hexal and Teva
Success for Hexal and Teva

The phar­maceu­ti­cal com­pa­nies Hex­al and Teva may con­ti­nue to sell…

New Breakthrough for Hexal in the Fulvestrant Sage
New Breakthrough for Hexal in the Fulvestrant Sage

The patent dis­pu­tes of our cli­ent Hex­al AG over the…

Five IP-Stars go to the df-mp team
Five IP-Stars go to the df-mp team

df-mp is deligh­ted that five part­ners have been award­ed the…

First choice in the high-tech industry
First choice in the high-tech industry

df-mp is recom­men­ded in the cur­rent JUVE-Han­d­­book with the hig­hest…

admissions.

  • German Patent Attorney
  • European Patent Attorney
  • European Trademark Attorney
  • European Design Attorney
  • European Patent Litigator

     EDUCATION

  • Pharmacy, University of Innsbruck (Mag. pharm.)
  • Doctorate degree in medicinal chemistry, University of Innsbruck,  (Dr. rer. nat.)
  • Postdoctoral research fellow at the Laboratory of Medicinal Chemistry at the National Institute of Health (NIH) in Bethesda, MD, U.S.A.

references and activities.

  • Author and co-author of numerous scientific publications in the field of organic and medicinal chemistry
  • Organizer of IP-workshops
  • Lecturer of IP-seminars at the MCI (Management Center Innsbruck, the entrepreneurial school, Austria)
  • Elisabeth has been listed in the IAM patent 1000 as recommended individual (one of the top pharmaceutical patent practitioners“, „outstanding at communicating her technical points to technical judges; her pleading style is genuinely impressive. She is hard-working, dedicated, articulate and creative“), JUVE-Handbook („cooperative, friendly and highly experienced in infringement cases”, “impressive in pharmaceuticals cases”), and also regularly as IP star in the Managing Intellectual Property Magazine.

curriculum vitae.

Since 2012
Since 2012

Part­ner at df-mp

Since 2008
Since 2008

Patent att­or­ney at df-mp

2005-2008
2005-2008

Legal trai­nee at df-mp, the Ger­man Patent and Trade­mark Office (DPMA) and the Ger­man Fede­ral Patent Court (BPatG)

2001-2005
2001-2005

Post­doc­to­ral rese­arch fel­low in the Labo­ra­to­ry of Medi­cinal Che­mis­try at the Natio­nal Insti­tu­te of Health (NIH) in Bethes­da, MD, U.S.A.

1999-2000
1999-2000

Doc­to­ra­te Degree (with honors) in Medi­cinal Che­mis­try from Uni­ver­si­ty of Inns­bruck, Insti­tu­te of Phar­ma­cy, Aus­tria

1996
1996

Degree (Mag.pharm. with honors) in Medi­cinal Che­mis­try from Uni­ver­si­ty of Inns­bruck, Insti­tu­te of Phar­ma­cy, Aus­tria

Representative cases.

  • Glatirameracetat / Copaxone®infringement proceedings, utility model cancellation proceedings
  • Fulvestrant / Faslodex®Formulation patents, nullity proceedings (BGH X ZR 59/17), opposition proceedings, various infringement proceedings
  • Fulvestrant / Faslodex®Patent of use, infringement proceedings
  • Calcipotriol – Betamethason /  Calcipotriol comp Hexal®several opposition proceedings, infringement proceedings
  • DMF / Tecfidera®various opposition procedures
  • Anti-VEGF Antibody / Avastin® Xeloda®opposition procedures

association memberships.

  

publications.

  • Greiner, E.; Schottenberger, H.; Wurst, K.; Schmidhammer, H.: Novel Class of Morphinans with Acrylonitrile Incorporated Substructures as Key Intermediates for non-Oxygen-Bridged Opioid Ligands. J. Am. Chem. Soc. 2001, 123, 3840-3841.
  • Greiner, E.; Atkinson, A.J.J.; Ayala, A.; Chrousos, G.P.; Contoreggi, C.; Eckelman, W.C.; Gold, P.W.; Habib, K.E.; Jacobson, A.E.; Webster, E.L.; Rice K.C.: Synthesis of Doubly 13C-Labelled Antalarmin Isotopomers for Pharmacokinetic Studies. J. Labelled Cpd. Radiopharm. 2002, 45, 637-645.
  • Greiner, E.; Prisinzano, T.; Johnson II, E.M.; Dersch, C.M.; Marcus, J.; Rothman, R.B.; Jacobson, A.E.; Rice, K.C.: Structure-activity relationship studies of highly selective inhibitors of the dopamine transporter: N-benzylpiperidine analogues of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine. J. Med. Chem. 2003, 46, 1465-1469.
  • Greiner, E.; Spetea, M.; Krassnig, R.; Schuellner, F.; Aceto, M.; Harris, L.S.; Traynor, J.R.; Woods, J.H.; Winger, G.; Coop, A.; Schmidhammer, H.: Synthesis and Biological Evaluation of 14-Alkoxymorphinans - Part 18 - N-Substituted 14-Phenylpropyloxymorphinan-6-ones with Unanticipated Agonist Properties: Extending the Scope of Common Structure-Activity Relationships. J. Med. Chem. 2003, 46, 1758-1763.
  • Jagoda, E.; Contoreggi, C.; Lee, M.; Kao, C.K.; Szajak, L.P.; Listwak, S.; Gold, P.W.; Chrousos, G.P.; Greiner, E.; Kim B.M., Jacobson, A.E.; Rice K.C.: Eckelman, W.: Autoradiographic visualization of corticotropin releasing hormone type 1 receptors with a nonpeptide ligand: Synthesis of [Br-76]MJL-1-109-2. J. Med. Chem. 2003, 46, 3559-3562.
  • Greiner, E.; Folk, J.E.; Jacobson, A.E.; Rice, K.C.: A novel and facile preparation of bremazocine enantiomers through optically pure N-norbremazocines. Bioorg. Med. Chem. 2004, 12, 223-238.
  • Seggewiss, R.; Lore, K.; Greiner E.; Magnusson M.K.; Price D.A.; Douek D.C.; Dunbar C.E.; Wiestner A.: Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 2005, 15, 2473-2479.
  • Greiner, E.; Boos, T.L.; Prisinzano T.E.; De Martino, M.G.; Zeglis, B.; Dersch, C.M.; Marcus, J.; Partilla, J.S.; Rothman, R.B.; Jacobson, A.E.; Rice, K.C.: Design and Synthesis of Promiscuous High Affinity Monoamine Transporter Ligands: An Attempt at Unraveling Transporter Selectivity. J. Med. Chem. 2006 Mar 9;49(5):1766-72.
  • Weichsel R, Dix C, Wooldridge L, Clement M, Fenton-May A, Sewell AK, Zezula J, Greiner E, Gostick E, Price DA, Einsele H, Seggewiss R. Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin Cancer Res. 2008 Apr 15;14(8):2484-91.